Ascletis Advances Once-Weekly Oral Obesity Drug to FDA
Hong Kong, November 17, 2026 Ascletis Pharma Inc. has submitted an Investigational New Drug (IND) application to the U.S....
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Hong Kong, November 17, 2026 Ascletis Pharma Inc. has submitted an Investigational New Drug (IND) application to the U.S....
Hong Kong, China, August 10, 2026 Ascletis Pharma Inc. has announced the initiation of two Phase I clinical studies...
Hong Kong, July 27, 2026 Ascletis Pharma Inc. announced that its investigational ASC37, a next-generation GLP-1R/GIPR/GCGR triple peptide agonist,...
HONG KONG, July 23, 2026 Ascletis Pharma Inc. has announced that new preclinical data for its investigational obesity therapy...
BEIJING, China, July 6, 2026 InnoCare Pharma has announced a significant milestone in its oncology pipeline with the first...
HONG KONG, July 6, 2026 Ascletis Pharma Inc. has announced the submission of two Investigational New Drug (IND) applications...
HONG KONG, June 23, 2026 Ascletis Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...
